ClinicalTrials.gov Trial Start Dates: Recruiting vs Actual Enrollment

A trial appears on ClinicalTrials.gov with a start date and a recruiting label. Has the first participant actually enrolled? Those fields answer different questions. Before treating a registry update as an investment catalyst, identify the exact study, the date type and what the record does not establish.

Substantially revised October 6, 2026 (America/Chicago). The earlier version overstated what completion dates, status changes and endpoint edits imply. This guide replaces those shortcuts with a source checklist. The examples below use records retrieved on that date; recheck the original record before using them in a current thesis.

Start with the NCT number and sponsor

Use the NCT identifier to keep evidence attached to one study. Record its lead sponsor, intervention, condition, phase and latest posted update. A drug name or ticker in an article URL is not proof that a listed company owns the program.

For example, TRIlogy-7, NCT07665450, identifies Janssen Research & Development, LLC as lead sponsor. Our earlier ramantamig article incorrectly associated it with GH Research; the correction withdraws that association. Do not build a GH Research thesis from that study or infer a replacement ticker from the sponsor name alone.

Does recruiting mean the trial has started?

Under the ClinicalTrials.gov protocol field definitions, recruiting means participants are being recruited; it does not require that a participant has already enrolled. The start-date field distinguishes a planned opening for recruitment from the reported actual date of first enrollment.

Field	What it supports	What it does not establish
Start date: ESTIMATED	A planned recruitment opening	First participant enrolled on that date
Start date: ACTUAL	A reported first-enrollment date	Completed enrollment or a successful treatment outcome
Recruiting	Recruitment is open according to the record	An exact first-enrollment date or recruitment pace
Enrollment: ESTIMATED	Target participant count	Participants already enrolled
Enrollment: ACTUAL	Reported enrolled count	Statistical power, efficacy or commercial success by itself

A registry field is a dated report from the responsible party. If a filing or company announcement disagrees, retain both sources and their dates. Do not silently combine them into an apparently certain timeline. An unverified actual start is UNKNOWN.

Worked examples: NVG-291 and NAI sepsis

The NVG-291 RESTORE record, NCT07799532, last posted October 5, 2026, lists Recruiting and an ACTUAL September 28, 2026 start. The actual label supplies the start evidence; recruiting alone would not. Its Phase 3 enrollment of 150 remains estimated. That target does not say 150 people have enrolled. Our dated RESTORE update preserves the distinction from the earlier estimated-start snapshot.

The NAI sepsis record, NCT07783789, last posted September 25, 2026, lists Not yet recruiting, an ESTIMATED October 15, 2026 start and estimated enrollment of 50. It does not supply an actual start date. The Phase 2 plan is research evidence, not proof that sepsis treatment has begun, worked or been approved. See the NAI correction for the changed design fields and remaining conflicts.

These records can change. The same checklist should be applied to the latest version rather than treating this article as a live registry feed.

Primary completion is not a promised public readout

ClinicalTrials.gov defines primary completion around the final collection of primary-outcome data from participants. Study completion covers the final collection for the primary and secondary outcomes and adverse events. Neither field is a promise about when results will be publicly announced.

RESTORE records July 2027 as estimated primary completion, with month precision. Preserve that precision: do not invent a day or turn July into a confirmed topline announcement. A separately verified sponsor disclosure would be needed to support a public readout expectation.

Similarly, completed status reports that the study concluded. It does not establish an imminent announcement, positive results or a posted results dataset. Check the results section and independently dated disclosures for the exact study. If results are absent, the result and release timing remain unknown.

Check design roles instead of relying on a blind label

Read allocation, comparator, masking roles and the primary outcome measures together. A registered design describes what investigators plan to test; it does not demonstrate treatment benefit. Outcome measures alone also do not prove that a study has sufficient statistical power.

RESTORE's official title uses double-blind while its structured masking field lists participant, care provider and investigator under triple masking. Report the roles explicitly. For NAI sepsis, the title says double-blind but the structured field specifies single masking of the participant, with additional roles described as applicable. That conflict requires clarification; do not choose the more reassuring label. The trial-design evidence checklist explains the questions to ask next.

An endpoint edit, enrollment reduction or date extension is a reason to investigate the protocol and explanation. It is not, by itself, evidence of failure, safety trouble or likely efficacy. Compare dated versions and seek an explicit reason before assigning one.

Turn the record into a research question

For a company and trial you can verify, write down:

1. Which NCT record and sponsor establish the program identity?
2. Which dates are actual, which are estimated, and at what precision?
3. What enrollment count is reported, and is it a target or an actual count?
4. What do the comparator, masking roles and outcomes allow us to assess?
5. Which results or sponsor disclosures support a readout claim, and what remains UNKNOWN?

Use the research entry on this page to select the company and verify the trial-status evidence. Review the prepared question and displayed usage estimate before choosing to run it. The article is background; a current answer still needs dated primary evidence and an explicit account of missing or conflicting information.

This checklist helps distinguish a study plan from an observed clinical event. It does not turn a registry change into a valuation conclusion or an investment recommendation.